Literature DB >> 17371907

Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration.

Y A L Pijnenburg1, S N M Schoonenboom, P D Mehta, S P Mehta, C Mulder, R Veerhuis, M A Blankenstein, P Scheltens.   

Abstract

The role of amyloid metabolism in the pathophysiology of frontotemporal lobar degeneration (FTLD) has yet to be elucidated. We compared CSF levels of amyloid beta 1-40 (Abeta40) and amyloid beta 1-42 (Abeta42) in patients with FTLD (n = 21) versus patients with Alzheimer's disease (AD, n = 39) and in control subjects (n = 30). While in AD cases Abeta42 levels were lower and CSF Abeta40 levels equal to those in controls, a significant decrease in Abeta40 and increase in the CSF Abeta42/Abeta40 ratio was observed in FTLD compared with AD and control subjects. These findings favour a differential involvement of amyloid beta peptides in FTLD compared with AD.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17371907      PMCID： PMC2117666          DOI： 10.1136/jnnp.2006.105064

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  16 in total

1.  Plasma amyloid beta protein 1-42 levels are increased in old Down Syndrome but not in young Down Syndrome.

Authors:  Pankaj D Mehta; Sangita P Mehta; Betty Fedor; Bruce A Patrick; Mark Emmerling; Arthur J Dalton
Journal:  Neurosci Lett       Date:  2003-05-22       Impact factor: 3.046

2.  Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

Authors:  P D Mehta; T Pirttilä; S P Mehta; E A Sersen; P S Aisen; H M Wisniewski
Journal:  Arch Neurol       Date:  2000-01

3.  Frontotemporal dementia: clinical, neuroimaging, and molecular biological findings in 6 patients.

Authors:  M Jauss; K Herholz; L Kracht; J Pantel; T Hartmann; M Jensen; M Essig; J Schröder
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2001-10       Impact factor: 5.270

4.  Coexistent tau and amyloid pathology in hereditary frontotemporal dementia with tau mutations.

Authors:  S M Rosso; W Kamphorst; R Ravid; J C van Swieten
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

5.  Amyloid beta protein deposition in patients with frontotemporal lobar degeneration: relationship to age and apolipoprotein E genotype.

Authors:  D M Mann; A M McDonagh; S M Pickering-Brown; H Kowa; T Iwatsubo
Journal:  Neurosci Lett       Date:  2001-05-25       Impact factor: 3.046

6.  Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease.

Authors:  G M McKhann; M S Albert; M Grossman; B Miller; D Dickson; J Q Trojanowski
Journal:  Arch Neurol       Date:  2001-11

Review 7.  CSF markers for incipient Alzheimer's disease.

Authors:  Kaj Blennow; Harald Hampel
Journal:  Lancet Neurol       Date:  2003-10       Impact factor: 44.182

8.  Familial frontotemporal dementia associated with a novel presenilin-1 mutation.

Authors:  D Tang-Wai; P Lewis; Bradley Boeve; M Hutton; T Golde; M Baker; J Hardy; V Michels; R Ivnik; C Jack; R Petersen
Journal:  Dement Geriatr Cogn Disord       Date:  2002       Impact factor: 2.959

9.  Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study.

Authors:  Bradley F Boeve; Matt Baker; Dennis W Dickson; Joseph E Parisi; Caterina Giannini; Keith A Josephs; Michael Hutton; Stuart M Pickering-Brown; Rosa Rademakers; David Tang-Wai; Clifford R Jack; Kejal Kantarci; Maria M Shiung; Todd Golde; Glenn E Smith; Yonas E Geda; David S Knopman; Ronald C Petersen
Journal:  Brain       Date:  2006-10-09       Impact factor: 13.501

10.  Soluble amyloid beta-protein is increased in frontotemporal dementia with tau gene mutations.

Authors:  Antonella Vitali; Alessandra Piccini; Roberta Borghi; Pantaleo Fornaro; Sandra L Siedlak; Mark A Smith; Pierluigi Gambetti; Bernardino Ghetti; Massimo Tabaton
Journal:  J Alzheimers Dis       Date:  2004-02       Impact factor: 4.472
View more
  12 in total

1.  An integrated microfluidic chip for immunocapture, preconcentration and separation of β-amyloid peptides.

Authors:  Reza M Mohamadi; Zuzana Svobodova; Zuzana Bilkova; Markus Otto; Myriam Taverna; Stephanie Descroix; Jean-Louis Viovy
Journal:  Biomicrofluidics       Date:  2015-10-01       Impact factor: 2.800

2.  Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration.

Authors:  Petra Steinacker; Corinna Hendrich; Anne-Dorte Sperfeld; Sarah Jesse; Stefan Lehnert; Alice Pabst; Christine A F von Arnim; Felix M Mottaghy; Ingo Uttner; Hayrettin Tumani; Albert Ludolph; Markus Otto
Journal:  J Neural Transm (Vienna)       Date:  2009-08-01       Impact factor: 3.575

3.  Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method.

Authors:  Magdalena Korecka; Michal J Figurski; Susan M Landau; Magdalena Brylska; Jacob Alexander; Kaj Blennow; Henrik Zetterberg; William J Jagust; John Q Trojanowski; Leslie M Shaw
Journal:  Clin Chem       Date:  2020-04-01       Impact factor: 8.327

4.  Neurochemical biomarkers in Alzheimer's disease and related disorders.

Authors:  Mirko Bibl; Hermann Esselmann; Jens Wiltfang
Journal:  Ther Adv Neurol Disord       Date:  2012-11       Impact factor: 6.570

Review 5.  Biological fluid biomarkers in neurodegenerative parkinsonism.

Authors:  Michael Eller; David R Williams
Journal:  Nat Rev Neurol       Date:  2009-09-01       Impact factor: 42.937

6.  Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria.

Authors:  Dimitri Renard; Giovanni Castelnovo; Anne Wacongne; Anne Le Floch; Eric Thouvenot; Julie Mas; Audrey Gabelle; Pierre Labauge; Sylvain Lehmann
Journal:  J Neurol       Date:  2012-05-11       Impact factor: 4.849

Review 7.  Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?

Authors:  Kurt A Jellinger; Bernd Janetzky; Johannes Attems; Elisabeth Kienzl
Journal:  J Cell Mol Med       Date:  2008-03-19       Impact factor: 5.310

8.  Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders.

Authors:  Everard G B Vijverberg; Annemiek Dols; Welmoed A Krudop; Marta Del Campo Milan; Cora J Kerssens; Flora Gossink; Niels D Prins; Max L Stek; Philip Scheltens; Charlotte E Teunissen; Yolande A L Pijnenburg
Journal:  Alzheimers Dement (Amst)       Date:  2017-03-02

9.  Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease.

Authors:  David J Irwin; John Q Trojanowski; Murray Grossman
Journal:  Front Aging Neurosci       Date:  2013-02-21       Impact factor: 5.750

Review 10.  Amyloid-β and Astrocytes Interplay in Amyloid-β Related Disorders.

Authors:  Yazan S Batarseh; Quoc-Viet Duong; Youssef M Mousa; Sweilem B Al Rihani; Khaled Elfakhri; Amal Kaddoumi
Journal:  Int J Mol Sci       Date:  2016-03-04       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.